Anne M. Ercolini

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Jean-Pascal Machiels, R. Todd Reilly, Leisha A. Emens et al. · PubMed · 2001 · 459 citations

Immunology, Immunoediting, Immunologic Mechanism +19

Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

Anne M. Ercolini, Brian H. Ladle, Elizabeth A. Manning et al. · The Journal of Experimental Medicine · 2005 · 396 citations · Full text

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

R. Todd Reilly, Morris B.C. Gottlieb, Anne M. Ercolini et al. · PubMed · 2000 · 216 citations

Knockout Mouse, Radiation Oncology, Cancer Immunosurveillance +15

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

R. Todd Reilly, Jean-Pascal Machiels, Leisha A. Emens et al. · PubMed · 2001 · 152 citations

Immunology, Neu-n Mice, Immunologic Mechanism +19

HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/ <i>neu</i> -Transgenic Mice

Matthew E. Wolpoe, Eric R. Lutz, Anne M. Ercolini et al. · The Journal of Immunology · 2003 · 104 citations · Full text